MA37664A1 - Formulation pour implant contenant de la rispéridone et/ou de la palipéridone - Google Patents
Formulation pour implant contenant de la rispéridone et/ou de la palipéridoneInfo
- Publication number
- MA37664A1 MA37664A1 MA37664A MA37664A MA37664A1 MA 37664 A1 MA37664 A1 MA 37664A1 MA 37664 A MA37664 A MA 37664A MA 37664 A MA37664 A MA 37664A MA 37664 A1 MA37664 A1 MA 37664A1
- Authority
- MA
- Morocco
- Prior art keywords
- paliperidone
- risperidone
- weeks
- formulation containing
- lactic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Cette invention concerne une composition retard injectable par voie intramusculaire adaptée à former in situ un implant solide dans le corps. La composition comprend de la rispéridone et/ou de la palipéridone (médicaments) et/ou l'un quelconque de leurs sels pharmaceutiques acceptables, quelle que soit leur combinaison, un copolymère biocompatible à base d'acide lactique et d'acide glycolique dont le rapport monomère acide lactique sur acide glycolique se situe dans la plage 50:50, et du dmso pour solvant. La composition libère la rispéridone et/ou de la palipéridone immédiatement et en continu pendant au moins 4 semaines, son profil pharmacocinétique in vivo permettant que la formulation soit administrée toutes les 4 semaines ou sur des périodes plus longues.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170362.3A EP2529756B1 (fr) | 2011-05-31 | 2012-05-31 | Formulation d'implant de rispéridone et/ou de palipéridone |
| PCT/EP2013/061320 WO2013178812A1 (fr) | 2012-05-31 | 2013-05-31 | Formulation pour implant contenant de la rispéridone et/ou de la palipéridone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37664A1 true MA37664A1 (fr) | 2016-03-31 |
| MA37664B1 MA37664B1 (fr) | 2016-11-30 |
Family
ID=46147376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37664A MA37664B1 (fr) | 2012-05-31 | 2014-12-16 | Formulation pour implant contenant de la rispéridone et/ou de la palipéridone |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP2529756B1 (fr) |
| JP (1) | JP6367795B2 (fr) |
| KR (1) | KR101880716B1 (fr) |
| CN (1) | CN104363923A (fr) |
| AU (1) | AU2013269547B2 (fr) |
| BR (1) | BR112014029209A2 (fr) |
| CA (1) | CA2874765C (fr) |
| CL (1) | CL2014003216A1 (fr) |
| CO (1) | CO7160108A2 (fr) |
| CY (1) | CY1124369T1 (fr) |
| DK (2) | DK2529756T3 (fr) |
| EA (1) | EA031819B1 (fr) |
| ES (2) | ES2878112T3 (fr) |
| FI (1) | FI2854858T3 (fr) |
| HR (2) | HRP20260301T1 (fr) |
| IL (1) | IL235849B (fr) |
| IN (1) | IN2014DN10672A (fr) |
| LT (2) | LT2529756T (fr) |
| MA (1) | MA37664B1 (fr) |
| MX (1) | MX374955B (fr) |
| MY (1) | MY174999A (fr) |
| NZ (1) | NZ703321A (fr) |
| PH (1) | PH12014502667B1 (fr) |
| PL (2) | PL2529756T3 (fr) |
| PT (2) | PT2529756T (fr) |
| RS (1) | RS62059B1 (fr) |
| SG (1) | SG11201407961WA (fr) |
| SI (2) | SI2529756T1 (fr) |
| SM (1) | SMT202100448T1 (fr) |
| UA (1) | UA119430C2 (fr) |
| WO (1) | WO2013178812A1 (fr) |
| ZA (1) | ZA201409299B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| EP2529757B1 (fr) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Formulation d'implant de Paliperidone |
| SI2394663T1 (sl) | 2010-05-31 | 2022-02-28 | Laboratorios Farmaceuticos Rovi, S.A. | Sestave za injicirane biološko razgradljive vsadke in situ |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| LT2529756T (lt) * | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
| EP2986278A1 (fr) | 2013-03-11 | 2016-02-24 | DURECT Corporation | Composition injectable à libération contrôlée comprenant un véhicule liquide à haute viscosité |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| CN104922085B (zh) * | 2015-06-01 | 2016-10-26 | 湖南赛沃药业有限公司 | 一种利培酮植入剂及其制备方法 |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| WO2019222856A1 (fr) | 2018-05-24 | 2019-11-28 | Nureva Inc. | Procédé, appareil et supports lisibles par ordinateur pour gérer des sources sonores semi-constantes (persistantes) dans des zones de capture/foyer de microphones |
| AU2019275406B2 (en) | 2018-05-24 | 2024-11-14 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| WO2019226519A1 (fr) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| WO2022231930A1 (fr) | 2021-04-26 | 2022-11-03 | Celanese Eva Performance Polymers Llc | Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| US12594236B2 (en) | 2021-07-16 | 2026-04-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| EP4527389A4 (fr) | 2022-05-18 | 2026-05-06 | Farm Rovi Lab Sa | Compositions injectables à libération prolongée destinées à être utilisées dans le cadre du traitement par rispéridone en association avec des inhibiteurs de l'enzyme cyp2d6 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE288270T1 (de) | 1993-11-19 | 2005-02-15 | Janssen Pharmaceutica Nv | Mikroverkapselte 1,2-benzazole |
| WO2004064752A2 (fr) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Procede de preparation de microparticules a liberation prolongee |
| JP2008518881A (ja) * | 2003-07-18 | 2008-06-05 | オークウッド ラボラトリーズ，エル．エル．シー． | 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止 |
| KR101340946B1 (ko) | 2004-08-04 | 2013-12-13 | 알자 코포레이션 | 오름차 0차 방출 패턴을 나타내는 약물의 서방성 조성물,상기 조성물을 제조하는 방법 |
| US8314110B2 (en) | 2007-04-19 | 2012-11-20 | Youxin Li | Compounds for treating mental disorders, and preparation and uses thereof |
| WO2008143992A2 (fr) * | 2007-05-18 | 2008-11-27 | Durect Corporation | Formulations à dépôt amélioré |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| WO2009015828A1 (fr) | 2007-07-27 | 2009-02-05 | Synthon B.V. | Dérivés de palipéridone |
| CN101932327A (zh) | 2007-12-19 | 2010-12-29 | 詹森药业有限公司 | 与长效注射用帕潘立酮酯相关的给药方案 |
| WO2011042453A1 (fr) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Composition sous-cutanée de palipéridone |
| EP2529757B1 (fr) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Formulation d'implant de Paliperidone |
| ES2589106T3 (es) * | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| SI2394663T1 (sl) * | 2010-05-31 | 2022-02-28 | Laboratorios Farmaceuticos Rovi, S.A. | Sestave za injicirane biološko razgradljive vsadke in situ |
| LT2529756T (lt) * | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
-
2012
- 2012-05-31 LT LTEP12170362.3T patent/LT2529756T/lt unknown
- 2012-05-31 SI SI201231933T patent/SI2529756T1/sl unknown
- 2012-05-31 RS RS20210834A patent/RS62059B1/sr unknown
- 2012-05-31 ES ES12170362T patent/ES2878112T3/es active Active
- 2012-05-31 PL PL12170362T patent/PL2529756T3/pl unknown
- 2012-05-31 PT PT121703623T patent/PT2529756T/pt unknown
- 2012-05-31 SM SM20210448T patent/SMT202100448T1/it unknown
- 2012-05-31 DK DK12170362.3T patent/DK2529756T3/da active
- 2012-05-31 EP EP12170362.3A patent/EP2529756B1/fr active Active
-
2013
- 2013-05-31 CA CA2874765A patent/CA2874765C/fr active Active
- 2013-05-31 SG SG11201407961WA patent/SG11201407961WA/en unknown
- 2013-05-31 JP JP2015514533A patent/JP6367795B2/ja active Active
- 2013-05-31 WO PCT/EP2013/061320 patent/WO2013178812A1/fr not_active Ceased
- 2013-05-31 LT LTEPPCT/EP2013/061320T patent/LT2854858T/lt unknown
- 2013-05-31 EP EP13726003.0A patent/EP2854858B1/fr active Active
- 2013-05-31 NZ NZ703321A patent/NZ703321A/en unknown
- 2013-05-31 FI FIEP13726003.0T patent/FI2854858T3/fi active
- 2013-05-31 PT PT137260030T patent/PT2854858T/pt unknown
- 2013-05-31 HR HRP20260301TT patent/HRP20260301T1/hr unknown
- 2013-05-31 AU AU2013269547A patent/AU2013269547B2/en active Active
- 2013-05-31 DK DK13726003.0T patent/DK2854858T3/da active
- 2013-05-31 CN CN201380027927.8A patent/CN104363923A/zh active Pending
- 2013-05-31 EA EA201401346A patent/EA031819B1/ru unknown
- 2013-05-31 BR BR112014029209A patent/BR112014029209A2/pt not_active Application Discontinuation
- 2013-05-31 IN IN10672DEN2014 patent/IN2014DN10672A/en unknown
- 2013-05-31 MX MX2014014483A patent/MX374955B/es active IP Right Grant
- 2013-05-31 ES ES13726003T patent/ES3064200T3/es active Active
- 2013-05-31 MY MYPI2014703551A patent/MY174999A/en unknown
- 2013-05-31 SI SI201332120T patent/SI2854858T1/sl unknown
- 2013-05-31 KR KR1020147035300A patent/KR101880716B1/ko active Active
- 2013-05-31 PL PL13726003.0T patent/PL2854858T3/pl unknown
- 2013-05-31 UA UAA201414187A patent/UA119430C2/uk unknown
-
2014
- 2014-11-23 IL IL235849A patent/IL235849B/en active IP Right Grant
- 2014-11-26 CL CL2014003216A patent/CL2014003216A1/es unknown
- 2014-11-28 PH PH12014502667A patent/PH12014502667B1/en unknown
- 2014-12-16 MA MA37664A patent/MA37664B1/fr unknown
- 2014-12-17 ZA ZA2014/09299A patent/ZA201409299B/en unknown
- 2014-12-30 CO CO14285844A patent/CO7160108A2/es unknown
-
2021
- 2021-07-02 HR HRP20211057TT patent/HRP20211057T1/hr unknown
- 2021-07-16 CY CY20211100644T patent/CY1124369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37664B1 (fr) | Formulation pour implant contenant de la rispéridone et/ou de la palipéridone | |
| MA37661B1 (fr) | Formulation pour implant contenant de la palipéridone | |
| EP4344702A3 (fr) | Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux | |
| EA200970348A1 (ru) | Новые инъецируемые депо-композиции и способ получения таких композиций | |
| EP4566670A3 (fr) | Modulateurs des propriétés pharmacocinétiques d'agents thérapeutiques | |
| MA34296B1 (fr) | Composition retard injectable antipsychotique | |
| AR082561A1 (es) | Forma de dosificacion farmaceutica que comprende 6’-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan-1,1’-pirano[3,4,b]indol]-4-amina | |
| CY1112499T1 (el) | Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων | |
| RU2014102940A (ru) | Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения | |
| DK2579874T3 (da) | Injicerbar, flydende sammensætning omfattende buprenorphin | |
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| EA201491870A1 (ru) | Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента | |
| TW200722420A (en) | Propane-1,3-dion derivative or salt thereof | |
| EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
| EA201070923A1 (ru) | Комбинация бис-тиазолиевой соли или одного из её предшественников и артемизинина и одного из его производных для лечения тяжелой формы малярии | |
| UA110933C2 (uk) | Композиція для лікування есенціальної тромбоцитемії | |
| CL2020000124A1 (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil. | |
| JOP20210068B1 (ar) | محاليل الزولبيديم أو أملاح مقبولة صيدلانيًا منه عبر الغشاء المخاطي الفموي | |
| BR112018017005A2 (pt) | composto derivado de entecavir e composição farmacêutica para prevenir ou tratar hepatite b | |
| MA49557B1 (fr) | Formulations à action prolongée | |
| FR3054134B1 (fr) | Formulation pharmaceutique de cineol et d'amoxicilline | |
| MA40372B1 (fr) | Formulation pharmaceutique de cineol et d'amoxicilline | |
| MA39084A1 (fr) | Formulation pharmaceutique de cineol et d'amoxicilline | |
| TN2013000480A1 (fr) | Composition pharmaceutique effervescente à base de sildénafil et son procédé de fabrication |